Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

USPIO Enhanced MR Imaging in CNS Tumours (UMIC) : A Pilot Study of Ferumoxytol (Feraheme ©) as an Imaging Biomarker of Tumour Associated Macrophage (TAM) Infiltration in Vestibular Schwannoma (VS) and Transforming Low Grade Glioma (LGG)

NCT06572475 is registered in ClinicalTrials.gov with Northern Care Alliance NHS Foundation Trust as lead sponsor.

NCT NCT06572475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06572475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
USPIO Enhanced MR Imaging in CNS Tumours (UMIC) : A Pilot Study of Ferumoxytol (Feraheme ©) as an Imaging Biomarker of Tumour Associated Macrophage (TAM) Infiltration in Vestibular Schwannoma (VS) and Transforming Low Grade Glioma (LGG)
Lead sponsor
Northern Care Alliance NHS Foundation Trust
Phase
Not applicable
Overall status
Recruiting
Start date
April 26, 2024
Completion date
December 31, 2026
Enrollment
17 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, astrocytic, vestibular schwannoma